Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences
March 04 2021 - 5:03PM
Business Wire
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare
leader developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound, eye,
oral and nasal care, disinfectant use and dermatological
conditions, today announced that CEO Amy Trombly and CFO Jerry
Dvonch will present at the following upcoming virtual
conferences.
Event
H.C. Wainwright Global Life Sciences
Conference
Date
March 9-10, 2021
Presentation
Available on demand beginning March 9,
2021
Event
Maxim Emerging Growth Conference
Date
March 17-18, 2021
Presentation
Available on demand beginning March 17,
2021
Investors interested in arranging a meeting with the Company’s
management for these conferences should contact the respective
conference coordinator.
The presentations and panel will be available for registered
attendees of each conference to view. Access to the H.C. Wainwright
conference presentation will be available HERE. Access to the Maxim
conference presentation will be available HERE. In addition, the
presentation was furnished on a current report on Form 8-K with the
U.S. Securities and Exchange Commission via EDGAR.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for
developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
animal health care, eye care, nasal care, oral care and
dermatological conditions. The company’s products reduce
infections, itch, pain, scarring and harmful inflammatory responses
in a safe and effective manner. In-vitro and clinical studies of
hypochlorous acid (HOCl) show it to have impressive antipruritic,
antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s
stabilized HOCl immediately relieves itch and pain, kills pathogens
and breaks down biofilm, does not sting or irritate skin and
oxygenates the cells in the area treated assisting the body in its
natural healing process. The company’s products are sold either
directly or via partners in 54 countries worldwide and the company
actively seeks new distribution partners. The company’s principal
office is in Woodstock, Georgia, with manufacturing operations in
Latin America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at
www.sonomapharma.com. For partnership opportunities, please contact
businessdevelopment@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “company”). These
forward-looking statements are identified by the use of words such
as “continue,” “develop” and “expand,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks that
regulatory clinical and guideline developments may change,
scientific data may not be sufficient to meet regulatory standards
or receipt of required regulatory clearances or approvals, clinical
results may not be replicated in actual patient settings,
protection offered by the company’s patents and patent applications
may be challenged, invalidated or circumvented by its competitors,
the available market for the company’s products will not be as
large as expected, the company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to meet the company’s cash needs, fund further
development, as well as uncertainties relative to the COVID-19
pandemic and economic development, varying product formulations and
a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the company’s filings with the Securities and
Exchange Commission. The company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ is a trademark or registered trademarks
of Sonoma Pharmaceuticals, Inc. All other trademarks and service
marks are the property of their respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210304006115/en/
Media and Investor Contact: Sonoma Pharmaceuticals,
Inc. ir@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Apr 2023 to Apr 2024